Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505737 | 0.87 | TSHR (0.41) | USP30ALDH1A1HTTGAAF10 | |
| SCHEMBL4515875 | 0.84 | F10 (0.42) | USP30KDM4DKAT8PARP1F10 | |
| SCHEMBL4526111 | 0.84 | USP30 (0.33) | USP30KDM4DKAT8ALDH1A1HTT | |
| SCHEMBL4526115 | 0.84 | USP30 (0.33) | USP30KDM4DKAT8ALDH1A1HTT | |
| SCHEMBL7512228 | 0.84 | KDM4D (0.33) | USP30KDM4DALDH1A1HTTTNF | |
| SCHEMBL4501900 | 0.82 | ROCK2 (0.43) | KAT8IRAK4KAT6AKAT5GAA | |
| SCHEMBL4508683 | 0.81 | ACACB (0.42) | TNFIRAK4F10DRD2 | |
| SCHEMBL4515547 | 0.81 | KAT8 (0.38) | KDM4DKAT8KAT6AKAT5DRD2 | |
| SCHEMBL4500116 | 0.81 | PDE10A (0.35) | KDM4DKAT8ALDH1A1HTTKAT6A | |
| SCHEMBL4500109 | 0.81 | PDE10A (0.35) | KDM4DKAT8ALDH1A1HTTKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | USP30 4162/4885KDM4D 1866/4885KAT8 74/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | USP30 4136/4885KDM4D 1744/4885KAT8 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.